ࡱ > T bjbjss 8X 8 = D \, .
+ + + + + + + - ,0 + Q ; ; ; + , ; ' ; + " # t* " ' ,, 0 \, " , 0 0 # # B 0 I# > J , v $ + + / \, ; ; ; ; 0 : 7 Management of Parkinsons Disease
Professor C E Clarke
Professor of Clinical Neurology, Department of Neurology, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham and School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham, Birmingham
This review is based on the National Institute for Health and Clinical Excellence (NICE) guideline on the diagnosis and management of Parkinson's disease ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1 which will be updated in 2012.
When to Start Treatment in Parkinson's Disease
Once Parkinson's disease has been diagnosed, any therapy which can slow or halt progression should be commenced immediately. Such neuroprotective or disease modifying therapy does not exist at present. Many agents have been investigated for neuroprotective properties in vitro and in vivo without success. ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1
Most clinicians delay the introduction of symptomatic treatment until the patient has significant functional disability, i.e. when it is interfering with activities of daily living, on the basis that symptomatic therapy is unlikely to be effective for mild symptoms which are not interfering with life. However, this view may change if it is found that early symptomatic treatment slows progression, as has been suggested. ADDIN EN.CITE Schapira200616181618161817Schapira, AHObeso, JTiming of treatment initiation in Parkinson's disease: a need for a reappraisal?Annals of NeurologyAnnals of NeurologyAnn NeurolAnn559-56559320062
The results of the rasagiline delayed-start trials (TEMPO and ADAGIO) ADDIN EN.CITE ADDIN EN.CITE.DATA 3-4 suggest that immediate treatment with a symptomatically active drug may have a disease modifying effect. Analogous findings in trials with levodopa (ELLDOPA) ADDIN EN.CITE Fahn200415971597159717Fahn, S.Oakes, D.Shoulson, I.Kieburtz, K.Rudolph, A.Lang, A.Olanow, C. W.Tanner, C.Marek, K.Parkinson Study, GroupColumbia University, New York, USA. fahn@neuro.columbia.eduLevodopa and the progression of Parkinson's disease.[see comment]New England Journal of MedicineNew England Journal of MedicineN Engl J MedNEJM2498-508351242004Dec 9155909525 and selegiline (DATATOP) ADDIN EN.CITE Shoulson200216191619161917Shoulson, I.Oakes, D.Fahn, S.Lang, A.Langston, J. W.LeWitt, P.Olanow, C. W.Penney, J. B.Tanner, C.Kieburtz, K.Rudolph, A.Parkinson Study, GroupUniversity of Rochester Medical Center, Rochester, NY 14620, USA. ishoulson@mct.rochester.eduImpact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialAnnals of NeurologyAnnals of NeurologyAnn NeurolAnn604-125152002May121121076 imply that any symptomatic therapy may have a disease modifying effect. However, a delayed-start design trial with the dopamine agonist pramipexole (PROUD) showed a symptomatic effect only.
There are many reasons why we should be cautious in the interpretation of these trials: ADDIN EN.CITE ADDIN EN.CITE.DATA 7-8
In TEMPO, the results with the 1 mg dose were not significant and in ADAGIO, the results with the 2 mg dose were not significant. There is also the possibility of selection bias in all delayed start trials, with a tendency to recruit milder slowly progressive patients who can tolerate no treatment for 18 months, so the results may not be generalisable.
The positive results of both TEMPO and ADAGIO were based on differences below 2 total UPDRS units. It has recently been shown that a clinically meaningful difference in total UPDRS in early Parkinson's disease is at least 6 units. ADDIN EN.CITE Schrag200623272327232717Schrag, A.Sampaio, C.Counsell, N.Poewe, W.Royal Free and University College Medical School, University College London, London, United Kingdom. a.schrag@medsch.ucl.ac.ukMinimal clinically important change on the unified Parkinson's disease rating scaleMovement DisordersMovement DisordersMov DisordMD1200-72182006/05/05AgedAntiparkinson Agents/*therapeutic use*Disability EvaluationDopamine Agents/therapeutic useFemaleHumansIndoles/*therapeutic useMaleMiddle AgedParkinson Disease/*classification/drug therapy/*physiopathologyReproducibility of ResultsTreatment Outcome2006Aug0885-3185 (Print)16673410http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1667341010.1002/mds.20914eng9
This small benefit could be due to symptomatic non-specific effects on the musculoskeletal system rather than a true neuroprotective effect. The European Medicines Agency (EMA) requires evidence of an effect on a biomarker of disease progression as well as a clinical effect before it will give a product licence for neuroprotection.
Treating patients on diagnosis would increase the net cost of treatment. There is no evidence, at present, that this is a cost-effective policy change.
Treating patients earlier may result in more dopaminergic adverse reactions (i.e. nausea, vomiting, hypotension), along with impulse control disorders (e.g. pathological gambling, hypersexuality, punding). Earlier treatment may also expedite motor complications (i.e. dyskinesias and motor fluctuations.
In conclusion, we must consider whether enough evidence has accumulated to change practice. If not, then we may need to perform further trials.
Management of Early Parkinson's Disease
Once motor symptoms interfere with everyday life, the NICE guidelines recommend commencing an agent from one of three first line drug classes: levodopa, dopamine agonists or monoamine oxidase type B (MAOB) inhibitors (Table 1). Evidence from randomised controlled trials and systematic reviews supports the efficacy of each of these drug classes. ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1 It was previously not clear which class to choose in any given clinical situation. For instance, many adopted the policy of using a dopamine agonist in younger patients to delay the onset of motor complications (abnormal involuntary movements, end of dose wearing off and unpredictable on-off switching) which are more frequent if treatment is initiated with levodopa. ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1 However, levodopa treats motor symptoms better than dopamine agonists and many young patients may still require fine motor skills for work.
Table 1 O p t i o n s f o r i n i t i a l s y m p t o m a t i c t h e r a p y f o r P a r k i n s o n s d i s e a s e ( f r o m r e f 2 )
F i r s t c h o i c e o p t i o n D e g r e e o f s y m p t o m c o n t r o l R i s k o f s i d e e f f e c t s M o t o r c o m p l i c a t i o n s O t h e r a d v e r s e e v e n t s L e v o d o p a Y e s G o o d I n c r e a s e d I n c r e a s e d D o p a m i n e a g o n i s t s Y e s M o d erateReducedIncreasedMonoamine-oxidase-B inhibitorsYesLimitedReducedIncreasedAnticholinergicsNoLack of evidenceLack of evidenceLack of evidenceBeta-blockersNoLack of evidenceLack of evidenceLack of evidenceAmantadineNoLack of evidenceLack of evidenceLack of evidence
In an attempt to resolve this uncertainty, the Health Technology Assessment Programme funded the PD MED trial (www.pdmed.bham.ac.uk) which has been reported in abstract form. ADDIN EN.CITE Gray201238633863386317Gray, RPatel, S Ives, NRick, CJenkinson, CWheatley, KWilliams, ACClarke, CEPD MED Collaborators,A large randomised trial assessing quality of life in patients with early Parkinson's disease: Results from PD MED EARLYParkinsonism and Related DisordersParkinsonism and Related DisordersS3218Suppl 2201210 PD MED EARLY showed that levodopa was superior to levodopa-sparing therapy (with a dopamine agonist or MAOB inhibitor) in terms of patient-rated quality of life (using the Parkinson's Disease Questionnaire-39 scale) in spite of causing more dyskinesias. The size of the benefit of levodopa was clinically small, being equivalent to 6 months of disease progression on the PDQ-39 scale, but it was consistent across all age groups including younger patients.
These results suggest that all patients should have levodopa as their initial therapy. With disease progression over several years, the dose will need to be steadily increased, but the dose should be restricted to avoid triggering off dyskinesias prematurely. For patients with an average body weight, the initial dose of levodopa will be 100 mg tds (with meals) which can be increased to 100 mg five times per day (additional doses with mid-morning and mid-afternoon drinks) and finally 600 mg per day (double dose with breakfast). Thereafter, dyskinesias and/or wearing off will require adjuvant therapy.
Management of Later Parkinson's Disease
The majority of patients will eventually require levodopa, so motor complications are inevitable. At this stage, the NICE guidelines recommend adjuvant therapy to levodopa with either a dopamine agonist, a MAOB inhibitor or a catechol-O-methyl transferase (COMT) inhibitor (Table 2). ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1
A recent systematic review of all placebo controlled trials with these three drug classes suggested that the dopamine agonists and tolcapone were more effective than entacapone and MAOB inhibitors at reducing off time and levodopa dose without an excess of side effects. ADDIN EN.CITE ADDIN EN.CITE.DATA 11-12 However, this was based on indirect comparisons and in a predominantly younger patient population so the results may not be gener a l i s a b l e t o a l l p a t i e n t s . F u r t h e r e v i d e n c e f r o m h e a d - t o - h e a d t r i a l s i s r e q u i r e d .
T a b l e 2 O p t i o n s f o r a d j u v a n t t h e r a p y i n l a t e r P a r k i n s o n s d i s e a s e ( f r o m r e f 2 )
F i r s t c h o i c e o p t i o n D e g r e e o f s y m p t o m c o n t r o l R i s k o f s i d e e f f e c t s M o t o r c o m p l i c a t i o n s O ther adverse eventsDopamine agonistsYesModerateReducedIncreasedCatechol-O-methyltransferase inhibitorsYesModerateReducedIncreasedMonoamine-oxidase type B inhibitorsYesModerateReducedIncreasedAmantadineNoNot significantReducedIncreasedApomorphineNoLimitedReducedIncreased
The PD MED LATER trial randomised patients on levodopa with motor complications to any dopamine agonist, MAOB inhibitor or COMT inhibitor. ADDIN EN.CITE Clarke201238623862386217Clarke, CEPatel, SIves, NRick, CJenkinson, CWheatley, KWilliams, ACGray, RPD MED Collaborators,A large randomised trial assessing quality of life in patients with later PD: Results from PD MED LATERParkinsonism & Related DisordersParkinsonism & Related DisordersS3318Suppl 2201213 The key finding was the large drug withdrawal rate due to adverse effects which was similar with all three drug classes. After one year of treatment, around 33% had stopped the allocated treatment, rising to 50% withdrawal after two years. There was no benefit in quality of life in using a dopamine agonist compared with a MAOB inhibitor or COMT inhibitor. However, there was weak evidence that the MAOB inhibitors may be superior to entacapone in quality of life, MMSE and the rate of development of dementia, although further follow up is required to confirm these findings.
These results suggest that many patients will only be able to tolerate levodopa therapy and that attempts to introduce adjuvant agents should not be made. Further work from PD MED LATER should clarify which patients should avoid add-on therapy, but these are likely to be older patients and those with early signs of cognitive decline.
There is still little evidence to direct the choice between adjuvant drug classes, but there is some suggestion in PD MED that an MAOB inhibitor should be tried first. ADDIN EN.CITE Clarke201238623862386217Clarke, CEPatel, SIves, NRick, CJenkinson, CWheatley, KWilliams, ACGray, RPD MED Collaborators,A large randomised trial assessing quality of life in patients with later PD: Results from PD MED LATERParkinsonism & Related DisordersParkinsonism & Related DisordersS3318Suppl 2201213 There is no evidence comparing the efficacy of selegiline with rasagiline and the PD MED results seem to apply to both drugs. Selegiline should be tried first as it is less expensive, but switched to rasagiline if it is not tolerated. With disease progression, other adjuvant agents will be required, so many will have a dopamine agonist and a COMT inhibitor added at some point. This leads to rational polypharmacy with medium dose levodopa and other adjuvant agents.
In recent years, the ergot-derived dopamine agonists (i.e. bromocriptine, lisuride, pergolide and cabergoline) have been withdrawn from use in Parkinson's disease as they produce pleural, pericardial or peritoneal effusions and fibrosis and cardiac valvulopathy with pergolide and cabergoline. The non-ergot agonists (i.e. pramipexole, ropinirole and rotigotine) are less likely to produce such problems, but clinical experience has been much shorter. However, the non-ergot agonists do cause impulse control disorders which include pathological gambling, hypersexuality, punding (i.e. abnormal collecting and categorising behaviour). The DOMINION study found these in 14% of 3090 North American patients with Parkinson's disease. ADDIN EN.CITE ADDIN EN.CITE.DATA 14 It is important to warn patients and their carers about these problems before drug initiation and to monitor for their occurrence throughout treatment.
Management of Advanced Parkinson's Disease
Three randomised controlled trials were included in a Cochrane review of amantadine used to treat dyskinesias in later Parkinson's disease. ADDIN EN.CITE Crosby20039839835Crosby, N JK H O DeaneC E ClarkeAmantadine for dyskinesia in Parkinson's disease (Cochrane Review)The Cochrane Library2003Chichester, UKJohn Wiley & Sons, Ltd15 Whilst the number of patients included was small (n=53) and the trials short, the NICE guidelines recommended that amantadine be used as an anti-dyskinesia agent. ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1 It is best to start with just 100 mg once daily, titrating up through 100 mg bd then 100 mg tds and to warn patients about the rare side effect of livedo reticularis (i.e. mottled brown rash on the legs).
The dopamine agonist apomorphine is not effective orally due to extensive first-pass metabolism in the liver. It was developed as intermittent bolus injections to rescue patients from severe off periods or as a subcutaneous infusion for patients with many off periods. Both uses require continuous treatment with the antiemetic domperidone to prevent nausea and vomiting. Three small trials (n=56) documented the efficacy and safety of intermittent injections of apomorphine, but only observational studies are available for the continuous infusion. ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1 Nevertheless, the NICE guidelines approved both for use in treating motor complications which are intractable to changes in oral therapy.
The NICE guidelines were prepared before the continuous infusion of a levodopa gel directly into the jejunum (Duodopa) was licensed for the management of severe motor complications. Small trials showed that these infusions reduce off time and improve motor function, activities of daily living, and quality of life. ADDIN EN.CITE ADDIN EN.CITE.DATA 16-17 However, its use will be restricted by cost (30,000 pa) and the need for a gastrostomy in potentially ill patients.
In terms of which parenteral or surgical therapy to use in an individual patient, there are no head-to-head trials and few placebo controlled trials to guide such a choice. ADDIN EN.CITE Clarke200934183418341817Clarke, C. E.Worth, P.Grosset, D.Stewart, D.Department of Neurology, City Hospital, Birmingham, UK. c.e.clarke@bham.ac.ukSystematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's diseaseParkinsonism Relat DisordParkinsonism Relat Disord728-4115102009/10/07Antiparkinson Agents/*therapeutic useApomorphine/*therapeutic useDeep Brain Stimulation/*methodsHumansLevodopa/*therapeutic useParkinson Disease/drug therapy/*therapy2009Dec1873-5126 (Electronic)
1353-8020 (Linking)19805000http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19805000S1353-8020(09)00227-2 [pii]
10.1016/j.parkreldis.2009.09.005eng18 Therefore, decisions tend to be pragmatic and based on patient preference and treatment availability and cost: So, most patients elect for apomorphine infusion ahead of surgery, and in the NHS both must be considered before funding for levodopa gel infusion will be contemplated.
Surgery (see Chapter 9)
Improved understanding of the neural mechanism of Parkinson's disease showed that the subthalamic nucleus (STN) is overactive. ADDIN EN.CITE Crossman198723523523517A R CrossmanPrimate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disordersNeuroscienceNeuroscienceNeurosciNeurosci1-4021198719 This led to the development of bilateral subthalamic (STN) stimulation surgery to switch off this nucleus. There have been many uncontrolled case series of STN stimulation, and only recently four randomised controlled trials (RCT) ADDIN EN.CITE ADDIN EN.CITE.DATA 20-22 including the UK PD SURG trial. These showed that STN stimulation reduces off time and off time disability, so medication can be reduced, thereby reducing dyskinesia. Meta-analysis of the results of these RCTs shows a consistent improvement compared with deferred surgery at 6, 12 and 18 months of around 5 points in patient-rated quality of life (PDQ 39 summary index), a difference which has previously been shown to be clinically significant. ADDIN EN.CITE Schrag200623272327232717Schrag, A.Sampaio, C.Counsell, N.Poewe, W.Royal Free and University College Medical School, University College London, London, United Kingdom. a.schrag@medsch.ucl.ac.ukMinimal clinically important change on the unified Parkinson's disease rating scaleMovement DisordersMovement DisordersMov DisordMD1200-72182006/05/05AgedAntiparkinson Agents/*therapeutic use*Disability EvaluationDopamine Agents/therapeutic useFemaleHumansIndoles/*therapeutic useMaleMiddle AgedParkinson Disease/*classification/drug therapy/*physiopathologyReproducibility of ResultsTreatment Outcome2006Aug0885-3185 (Print)16673410http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1667341010.1002/mds.20914eng9
The NICE guidelines recommended STN stimulation for patients with motor complications refractory to best medical treatment, who are biologically fit with no clinically significant active co-morbidity, who are levodopa responsive and have no clinically significant active mental health problems (depression or dementia). ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1 Questions still remain about the long-term safety of STN stimulation, as depression and suicide may be more common, and more information on cost-effectiveness of this expensive procedure is required. This should come from follow up of the PD SURG cohort.
Non-motor Features of Parkinson's Disease (see Chapters 4 and 8)
The motor features of Parkinson's disease can be controlled reasonably well in most patients with the measures outlined above. It is the non-motor features of the disorder which now present the greatest management challenge, including dementia, psychosis, imbalance and falls, autonomic dysfunction, sleep disorders, and pain. The NICE guidelines found a paucity of treatment trials for non-motor features. ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1 What evidence there was related to mental health conditions, particularly dementia. The trial evidence to support the efficacy and safety of cholinesterase inhibitors for Parkinson's disease dementia was inadequate and further trials are required. ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1
Nursing and Allied Health Professional Interventions
Three randomised controlled trials assessed the efficacy of Parkinson's Disease Nurse Specialists versus standard care. ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1 The benefits of nurses related to the overall patient care experience and delivery of services rather than in outcome measures such as quality of life or health economics. Therefore, the NICE guidelines recommended Nurse Specialists for clinical monitoring and medication adjustment, a continuing point of contact for support, and a reliable source of information about clinical and social matters for patients and carers. ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1
The evidence for the use of physiotherapy, occupational therapy and speech and language therapy in Parkinson's disease is based on a small number of trials with few participants, but clinical experience suggests that they are valuable. ADDIN EN.CITE Deane200295895817Deane, KHOEllis-Hill, CJones, DWhurr, RBen-Shlomo, YPlayford, EDClarke, C ESystematic review of paramedical therapies for Parkinson's diseaseMovement DisordersMovement DisordersMov DisordMD984-99117Cochrane Review2002National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1, 23 The NICE guidelines concluded that all three interventions should be available to patients throughout the disease (Table 3). However, the NICE guidelines recommended that further large scale trials should be performed with these therapies, such as the ongoing UK PD REHAB trial (www.pdrehab.bham.ac.uk) and the PD COMM pilot trial.
Table 3 Roles of allied health professional interventions in Parkinson's disease ADDIN EN.CITE National Collaborating Centre for Chronic Conditions200615591559155927National Collaborating Centre for Chronic Conditions,National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care2006LondonRoyal College of Physicians1
PhysiotherapyGait re-education, improvement of balance and flexibilityEnhancement of aerobic capacityImprovement of movement initiationImprovement of functional independence, including mobility and activities of daily livingProvision of advice regarding safety in the home environmentOccupational therapyMaintenance of work and family roles, home care and leisure activitiesImprovement and maintenance of transfers and mobilityImprovement of personal self-care activities such as eating, drinking, washing and dressingEnvironmental issues to improve safety and motor functionCognitive assessment and appropriate interventionSpeech and language therapyImprovement of vocal loudness and pitch range, including speech therapy programmes such as Lee Silverman Voice TreatmentTeaching strategies to optimise speech intelligibilityEnsuring an effective means of communication is maintained throughout the
course of the disease, including use of assistive technologiesReview and management to support the safety and efficiency of swallowing to minimise the risk of aspiration.
Future Treatments
It is crucial that neuroprotective agents are found to slow or halt the progression of Parkinson's disease. However, there are fundamental questions about neuroprotection trial design, particularly delayed-start design trials ADDIN EN.CITE ADDIN EN.CITE.DATA 7-8 and futility studies. ADDIN EN.CITE Tilley200615231523152317Tilley, B. C.Palesch, Y. Y.Kieburtz, K.Ravina, B.Huang, P.Elm, J. J.Shannon, K.Wooten, G. F.Tanner, C. M.Goetz, G. C.Net-Pd InvestigatorsDepartment of Biostatistics, Bioinformatics & Epidemiology, Medical University of South Carolina, P.O. Box 250835, Charleston, SC 29425, USA. tilleybc@musc.eduOptimizing the ongoing search for new treatments for Parkinson disease: using futility designs.[see comment]NeurologyNeurologyNeurologyN628-336652006Mar 141653409924
Much effort has gone in to developing non-dopaminergic agents for parkinsonian symptoms and/or dyskinesias (e.g. the adenosine A2A receptor antagonist preladenant). However, many have proved disappointing in clinical trials, perhaps because the current toxin-based animal models do not truly reflect the underlying pathophysiology of Parkinson's disease. ADDIN EN.CITE Fox200616001600160017Fox, S. H.Lang, A. E.Brotchie, J. M.Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failureMovement DisordersMovement DisordersMov DisordMD1578-9421102006Oct1687475225
The prospect of neurorestoration with stem cell grafts continues to generate considerable attention. However, two trials of foetal midbrain grafts found that, whilst beneficial effects occur, severe off period involuntary movements developed which necessitated pallidotomy in some cases. ADDIN EN.CITE ADDIN EN.CITE.DATA 26-27 There have also been recent post mortem results from these early grafting trials showing the development of Lewy bodies in the grafts which suggests the pathological process in Parkinson's disease continues throughout life. ADDIN EN.CITE Olanow200928452845284517Olanow, C. W.Prusiner, S. B.Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA. warren.olanow@mssm.eduIs Parkinson's disease a prion disorder?Proceedings of the National Academy of Sciences of the United States of AmericaProceedings of the National Academy of Sciences of the United States of AmericaProc Natl Acad Sci U S A12571-2106312009/08/12HumansParkinson Disease/*etiologyPrion Diseases/*etiologyalpha-Synuclein/*physiology2009Aug 41091-6490 (Electronic)19666621http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1966662127222980906759106 [pii]
10.1073/pnas.0906759106eng28
It will be many years before stem cell implants are shown in large clinical trials to be free from tumour formation and capable of controlled dopamine release. In the meantime, various nerve growth factors may be shown to stimulate the development of remaining dopaminergic neurones. ADDIN EN.CITE Lang200616021602160217Lang, A. E.Gill, S.Patel, N. K.Lozano, A.Nutt, J. G.Penn, R.Brooks, D. J.Hotton, G.Moro, E.Heywood, P.Brodsky, M. A.Burchiel, K.Kelly, P.Dalvi, A.Scott, B.Stacy, M.Turner, D.Wooten, V. G.Elias, W. J.Laws, E. R.Dhawan, V.Stoessl, A. J.Matcham, J.Coffey, R. J.Traub, M.Toronto Western Hospital, University of Toronto, Ontario, Canada. lang@uhnres.utoronto.caRandomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.[see comment]Annals of NeurologyAnnals of NeurologyAnn NeurolAnn459-665932006Mar1642941129
Competing interests: CEC received honoraria for lectures, travel expenses for conferences, and unrestricted educational grants from Boehringer-Ingelheim, GlaxoSmithKline, Lundbeck, Orion Pharma, Novartis, Teva, UCB.
Further Reading
NICE guidelines (http://www.nice.org/)
Cochrane reviews (via National Library for Health or http://www.update-software.com/publications/cochrane/)
Clarke CE. Parkinson's disease in Practice. Royal Society of Medicine Press: London. Second Edition. 2006.
Information Resources
Parkinson's UK (http://www.parkinsons.org.uk/)
European Parkinson's Disease Association (http://www.epda.eu.com/)
Michael J Fox Foundation for Parkinson's disease research (http://www.michaeljfox.org/)
References
ADDIN EN.REFLIST 1. National Collaborating Centre for Chronic Conditions. National Institute for Health and Clinical Excellence (NICE) Guidelines - Parkinson's disease: diagnosis and management in primary and secondary care. London: Royal College of Physicians; 2006.
2. Schapira A, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for a reappraisal? Ann Neurol. 2006;59(3):559-65.
3. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24;361(13):1268-78.
4. Parkinson Study Group. A controlled, randomised, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-6.
5. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease.[see comment]. N Engl J Med. 2004 Dec 9;351(24):2498-508.
6. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002 May;51(5):604-12.
7. Clarke CE. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord. 2008 Apr 30;23(6):784-9.
8. Clarke CE, Patel S, Ives N, Rick C, Wheatley K, Gray R. Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? Mov Disord. 2011 Jun;26(7):1187-93.
9. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord. 2006 Aug;21(8):1200-7.
10. Gray R, Patel S, Ives N, Rick C, Jenkinson C, Wheatley K, et al. A large randomised trial assessing quality of life in patients with early Parkinson's disease: Results from PD MED EARLY. Parkinsonism and Related Disorders. 2012;18(Suppl 2):S32.
11. Stowe R, Ives N, Clarke CE, Handley K, Furmston A, Deane K, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord. 2011 Mar;26(4):587-98.
12. Stowe R, Ives N, Clarke CE, Deane K, Wheatley K, Gray R, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010(7):CD007166.
13. Clarke C, Patel S, Ives N, Rick C, Jenkinson C, Wheatley K, et al. A large randomised trial assessing quality of life in patients with later PD: Results from PD MED LATER. Parkinsonism & Related Disorders. 2012;18(Suppl 2):S33.
14. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010 May;67(5):589-95.
15. Crosby NJ, Deane KHO, Clarke CE. Amantadine for dyskinesia in Parkinson's disease (Cochrane Review). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd; 2003.
16. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.[see comment]. Neurology. 2005 Jan 25;64(2):216-23.
17. Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003 May-Jun;26(3):156-63.
18. Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec;15(10):728-41.
19. Crossman AR. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neurosci. 1987;21:1-40.
20. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, et al. A randomized trial of deep-brain stimulation for Parkinson's disease.[erratum appears in N Engl J Med. 2006 Sep 21;355(12):1289]. N Engl J Med. 2006 Aug 31;355(9):896-908.
21. Schupbach WM, Maltete D, Houeto JL, du Montcel ST, Mallet L, Welter ML, et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology. 2007 Jan 23;68(4):267-71.
22. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ, Jr., et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009 Jan 7;301(1):63-73.
23. Deane K, Ellis-Hill C, Jones D, Whurr R, Ben-Shlomo Y, Playford E, et al. Systematic review of paramedical therapies for Parkinson's disease. Mov Disord. 2002;17:984-91.
24. Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, et al. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.[see comment]. Neurology. 2006 Mar 14;66(5):628-33.
25. Fox SH, Lang AE, Brotchie JM. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov Disord. 2006 Oct;21(10):1578-94.
26. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease.[see comment]. N Engl J Med. 2001 Mar 8;344(10):710-9.
27. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.[see comment]. Ann Neurol. 2003 Sep;54(3):403-14.
28. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12571-2.
29. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et a # $ . 9 Z 3 ? @ \
-
] ^ _ ` a b c
ļ|xtxtxmxix h[S hT\ h h;% h h, , h, , h, , H*mH nH u h\ j h Uh hA he\ 6h h 6 h 6he\ h\S 6he\ hR 6 h5 6 h*d hR he\ hb@ hR CJ aJ hb@ hA CJ aJ hb@ he\ CJ aJ hb@ hT"] CJ aJ ) $ 9 @ -
d ( F" " -$ s, - Z. / 0 B0 9 : : $If gd} $a$gd)v gd gdq9
& F h^hgdq9 gd;% gd gd;% gdA gdP Z gde\ gde\
$ % & ' ( S m n } ~ 7 8 ! ! ! ! ! ! ! ! ! ! " #" D" E" F" G" U" j" " " " " " " " " ٳٯՍ j~ h\ Uj h, , Uh^o hc% hc% hc% h h D h h, , h j h\ Uj h\ Uh\ h D h[S h h, , h, , H*mH nH u hC j h U 7" " " " " #
# ,$ -$ % % % o, p, q, r, s, , , - - +- ,- - - - - - - - - W. X. Y. Z. / / / / / / 0 0 A0 B0 0 0 0 0 0 0 0 0 &1 '1 1 1 4 4 4 4 4 ڿӻӻڳǣ ha h\ hG h1- hR h h|] h, h8 h\ j h Uh D hq9 hq9 hq9 hc% hc% hc% h, , h, , H*mH nH u j h, , U =4 4 t5 v5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 6 6 9 9 9 9 9 9 : : : : : : $; &; ,; R; T; |; ~; ; ; ; < < V< W< < < < < ʾ
hEnX CJ hv hv hv hv CJ hv hv CJ aJ h)v h0DW 56CJ j h)v hv 56CJ Uh)v hv 56CJ hgA h, , h, , H*mH nH u h\ j h UhFE hg3 h\S hEY
h\ hfU 2: : : $; $$If a$gd} $; &; (; / & $If gd} kd $$If l 4 \ rA#` ` `
t ( 0 6 4 4
l al p( (; *; ,; T; ~; $$If a$gd} ~; ; kd $$If l 4 r rA6 #
t 2 0 6 4 4
l al p2 ; ; ; ; ; ; $$If a$gdX& $$If a$gd} $If gd} ; ; ; ; < < N E 9 - - $$If a$gdX& $$If a$gd} $If gd} kd( $$If l r rA6 #
t 0 6 4 4
l al < < < 8< << D< B 9 - $$If a$gd} $If gd} kd $$If l r rA6 #
t 0 6 4 4
l al $$If a$gdX& D< L< V< W< h< k< B 9 - $$If a$gd} $If gd} kd $$If l r rA6 #
t 0 6 4 4
l al $$If a$gdX& k< |< < < < < B 9 $If gd} kdt $$If l r rA6 #
t 0 6 4 4
l al $$If a$gdX& < < < < < < 6 kd8 $$If l r rA6 #
t 0 6 4 4
l al $$If a$gdX& $$If a$gd} < < < = = %= $$If a$gdX& $$If a$gd} $If gd} < %= &= '= = = = = = = = = A A A A A nB B B C C E E F F F ,F 8F F F F F F F F F F :G ;G J ?J @J AJ QK Ͻ歩˕ h0W hci h, , h, , H*mH nH u j h UhI~ h#= hEY
hR h hB hpe hfp% h\ h\ H*mH nH u h\ j h\ UhC hC hC hfU h^o hv hv hv hv hv CJ aJ .%= &= '= C E F AJ L N I I I D I ? gd0W gde\ gd kd $$If l r rA6 #
t 0 6 4 4
l al QK RK aK bK vK wK xK yK ~K K L L L L FM HM M M M M M N N N FN GN PN QN N N N N N O O -O .O /O 3O :O @O Ź|tplhl hm hN hci hci CJ aJ h hci 6CJ aJ
hci CJ h hci h hci CJ h hci CJ aJ j h)v hci 56CJ Uh)v hci 56CJ h0W 56CJ h0W h\ h\ H*mH nH u j h\ Uj h\ Uh\ j h0W U (L L FM HM pM M M $$If a$gd $If gd $a$gdci gd0W M M M , # $If gd kd+ $$If l 4 \
]#`
` ` R
t ( 0 6 4 4
l al p( yt M M M M N $$If a$gd N N kd - $$If l 4 r
]3#
t 2 0 6 4 4
l al p2 yt N 'N +N 4N o o o o o o o p p p p p p $p %p -p 1p lp mp q q w w w w x x y y y 7y y y | | | | | } :} Q} m} s} t} } } } } } } } } } } ºֺ²ΦΦ춓䏈 h, hxG hxG jE h\ UhV hq` h^ hy^S h0DW h h\ j h( Uh[ hI ha hQ h h\ h\ H*mH nH u j h Uj h\ Uj|< h\ U 5} } } } } } } } } } } ~ ~ ~ .~ /~ K~ M~ |~ }~ ~ ~ ~ ~ ~ H c d Æ G % = N Ë Ћ ͻͻͳٳٳ h] hQ h h, , h, , H*mH nH u h\ j h Uh( hxG h, hV h\S h/" h/" hT\ h/" h0DW hq` C ) * = F G H ƌ ' ƍ ލ ߍ 7 8 9 ۑ ܑ ݔ ޔ ߔ ͻݷݷݷշͻ᭣ͻ͟ hVdA hM% h'4 hdr h 0J 5hdr h 0J 5h h, , h, , H*mH nH u h\ j h UhG[; h@- hp hs@ h3 hxG h;% hR h h/" hQ ; ? H ڙ ޙ ! . 9 : ; < = > ? ޝ * + \ ] b c d e ֤ ܤ ݤ ޤ h { μμvd #j h)v h 56CJ UaJ h)v h%M 56CJ aJ h)v hC*e 56CJ aJ hJ% h mH sH h( h( h( h^ h0DW h hC*e hy h-]U h\ h\ H*mH nH u hJ% h~ h h, , h, , H*mH nH u h\ j h Uh< hM% h'4 ' M N O P o p q r / 0 1 E F Ī Ū ƪ Ǫ " # $ % ^ _ ` a ( ) * h77 h%M 5CJ aJ hgt h%M hgt h%M CJ aJ hgt h%M CJ aJ mH sH h77 h%M 5CJ aJ mH sH h)v h%M 56CJ aJ (h, , h, , 56CJ H*aJ mH nH u #j h)v h 56CJ UaJ h\ 56CJ aJ 3N O P p z z $If gdgt z kd\` $$If l 0 #
t 0 6 4 4
l a p q r | | $If gdgt x kd` $$If l 0 #
t 0 6 4 4
l a | | $If gdgt x kdza $$If l 0 #
t 0 6 4 4
l a 0 | | $If gdgt x kdb $$If l 0 #
t 0 6 4 4
l a 0 1 F | | $If gdgt x kdb $$If l 0 #
t 0 6 4 4
l a Ū | | $If gdgt x kd!c $$If l 0 #
t 0 6 4 4
l a Ū ƪ Ǫ # | | $If gdgt x kdc $$If l 0 #
t 0 6 4 4
l a # $ % _ | | $If gdgt x kd;d $$If l 0 #
t 0 6 4 4
l a _ ` a | | $If gdgt x kdd $$If l 0 #
t 0 6 4 4
l a ) | | $If gdgt x kdUe $$If l 0 #
t 0 6 4 4
l a ) * + b | | $If gdgt x kde $$If l 0 #
t 0 6 4 4
l a * + a b c d \ ] ^ _ d o p ܭ ' 6 Q R a b v w x y | } ɳ ʳ ù|nff j h Uh( h( H*mH nH u jh h\ Uj h\ Uh\ j h( Uh?> hbe hl) h hy hdr hR 0J 5hdr h 0J 5 h%M h%M CJ aJ mH sH hgt h%M hgt h%M CJ aJ hgt h%M CJ aJ mH sH h77 h%M 5CJ aJ &b c d y n n $If gdgt d $If gdgt x kdof $$If l 0 #
t 0 6 4 4
l a \ | | $If gdgt x kdf $$If l 0 #
t 0 6 4 4
l a \ ] ^ p ϳ ~ y t o o o t t j e gdC*e gd gd:p gd gd%M `gd%M x kdg $$If l 0 #
t 0 6 4 4
l a ʳ ̳ ͳ γ ϳ
: E e f q ش 1 2 { | ~ ٹ 8 > G M S q s ƺ Ǻ Ⱥ ɺ κ Ϻ к C U ֳַַֻֿëà֜h, hxG j>s h\ Uj h\ Uh\S h@3 h] h h\ h#a' h' h:p h:p hjR h& h:p h h( j h Uh\ h\ H*mH nH u< D H / 0 g q ²}vohdhd]dY h8 hA` hC*e hC*e h hC*e hC*e hC*e h77 h h' CJ aJ mH sH hC*e h0 CJ aJ mH sH hC*e hsO CJ aJ hC*e hsO CJ aJ mH sH hC*e hsO 5CJ aJ mH sH hg
mH sH hjR hjR h\ h\ H*mH nH u hC h0 h@3 hs hjR h' j h U " 8 , & q % W l e D @ ( h ^h`gd\ gd $ a$ gdJe gdC*e gdC*e gdJe 6 * , g T T T T T T T T T T T T T T T T ɾɮɥ h,j h q h,j CJ ^J aJ h&; j h&; U h h U h\ h\ CJ aJ mH nH uh\ h CJ aJ j h\ h CJ UaJ h%M h hC*e hC*e hoJ hoJ hoJ h hC*e hA` hC*e # n H \ 8 3 X T T T T T T T T T T T $ h ^h`a$ gd\ h ^h`gd\ l. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.[see comment]. Ann Neurol. 2006 Mar;59(3):459-66.
T T T T T $ h ^h`a$ gd\ $a$gd q 6 &P 1h:pe\ . A!"#$% ~ D Olanow200931433143314317Olanow, C. W.Rascol, O.Hauser, R.Feigin, P. D.Jankovic, J.Lang, A.Langston, W.Melamed, E.Poewe, W.Stocchi, F.Tolosa, E.Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA. warren.olanow@mssm.eduA double-blind, delayed-start trial of rasagiline in Parkinson's diseaseNew England Journal of MedicineNew England Journal of MedicineN Engl J MedNEJM1268-78361132009/09/252009Sep 241533-4406 (Electronic)19776408http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19776408361/13/1268 [pii]
10.1056/NEJMoa0809335engParkinson Study Group200431423142314217Parkinson Study Group,A controlled, randomised, delayed-start study of rasagiline in early Parkinson diseaseArchives of NeurologyArchives of NeurologyArch NeurolArch561-566612004 ( D Clarke200816821682168217Clarke, C. E.Department of Neurology, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom. c.e.clarke@bham.ac.ukAre delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?Mov DisordMovement DisordersMov DisordMD784-92362008Apr 3018175348Clarke201137803780378017Clarke, C. E.Patel, S.Ives, N.Rick, C.Wheatley, K.Gray, R.Department of Neurology, City Hospital, Sandwell and West Birmingham NHS Trust, Dudley Road, Birmingham, United Kingdom. c.e.clarke@bham.ac.ukShould treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?Movement DisordersMovement DisordersMov DisordMD1187-932672011/04/16Antiparkinson Agents/*therapeutic use*Disability EvaluationEarly DiagnosisHumansParkinson Disease/*diagnosis/*drug therapy/physiopathologyWatchful Waiting/*methods2011Jun1531-8257 (Electronic)
0885-3185 (Linking)21495068http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2149506810.1002/mds.23519eng-$$If l !v h5 555m
#v #v#v#vm
:V l 4
t ( 0 6+ ++, 5 55 al p( Q$$If l !v h5 5555x#v #v#v#v#vx:V l 4
t 2 0 6+ ++, 5 55 al p2 $$If l !v h5 5555x#v #v#v#v#vx:V l
t 0 65 55 al $$If l !v h5 5555x#v #v#v#v#vx:V l
t 0 65 55 al $$If l !v h5 5555x#v #v#v#v#vx:V l
t 0 65 55 al $$If l !v h5 5555x#v #v#v#v#vx:V l
t 0 65 55 al $$If l !v h5 5555x#v #v#v#v#vx:V l
t 0 65 55 al $$If l !v h5 5555x#v #v#v#v#vx:V l
t 0 65 55 al " D Stowe201137813781378117Stowe, R.Ives, N.Clarke, C. E.Handley, K.Furmston, A.Deane, K.van Hilten, J. J.Wheatley, K.Gray, R.Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom. r.l.harrison@bham.ac.ukMeta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's diseaseMovement DisordersMovement DisordersMov DisordMD587-982642011/03/04Adjuvants, Pharmaceutic/*therapeutic useAntiparkinson Agents/*therapeutic useClinical Trials as TopicDisability EvaluationEnzyme Inhibitors/therapeutic useHumansLevodopa/*therapeutic useParkinson Disease/*drug therapyTreatment Outcome2011Mar1531-8257 (Electronic)
0885-3185 (Linking)21370258http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2137025810.1002/mds.23517engStowe201036343634363417Stowe, R.Ives, N.Clarke, C. E.Deane, K.Wheatley, K.Gray, R.Handley, K.Furmston, A.Birmingham Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK, B15 2TT.Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complicationsCochrane Database Syst RevCochrane Database Syst RevCD00716672010/07/09Antiparkinson Agents/adverse effects/*therapeutic useCatechol O-Methyltransferase/*antagonists & inhibitorsChemotherapy, AdjuvantDopamine Agonists/adverse effects/*therapeutic useDyskinesias/*drug therapy/etiologyHumansLevodopa/therapeutic useMonoamine Oxidase Inhibitors/adverse effects/*therapeutic useParkinson Disease/complications/*drug therapyRandomized Controlled Trials as Topic20101469-493X (Electronic)
1361-6137 (Linking)20614454http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2061445410.1002/14651858.CD007166.pub2eng;$$If l !v h5
555Q#v
#v#v#vQ:V l 4
t ( 0 6+ ++, 5
555Ral p( yt g$$If l !v h5
5555{ #v
#v#v#v#v{ :V l 4
t 2 0 6+ ++, 5
5555 al p2 yt $$If l !v h5
5555{ #v
#v#v#v#v{ :V l
t 0 65
5555 al yt $$If l !v h5
5555{ #v
#v#v#v#v{ :V l
t 0 65
5555 al yt $$If l !v h5
5555{ #v
#v#v#v#v{ :V l
t 0 65
5555 al yt $$If l !v h5
5555{ #v
#v#v#v#v{ :V l
t 0 65
5555 al yt $$If l !v h5
5555{ #v
#v#v#v#v{ :V l
t 0 65
5555 al yt D Weintraub201038143814381417Weintraub, D.Koester, J.Potenza, M. N.Siderowf, A. D.Stacy, M.Voon, V.Whetteckey, J.Wunderlich, G. R.Lang, A. E.University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. daniel.weintraub@uphs.upenn.eduImpulse control disorders in Parkinson disease: a cross-sectional study of 3090 patientsArchives of NeurologyArchives of NeurologyArch NeurolArch589-956752010/05/12AgedAntiparkinson Agents/*adverse effectsBenzothiazoles/adverse effectsBinge-Eating Disorder/chemically induced/epidemiologyComorbidityCross-Sectional StudiesFemaleGambling/psychologyHumansImpulse Control Disorders/*chemicallyinduced/*epidemiology/physiopathologyIndoles/adverse effectsLevodopa/adverse effectsMaleMiddle AgedParkinson Disease/*drug therapy/*epidemiologyPrevalenceRisk FactorsSexual Dysfunctions, Psychological/chemically induced/epidemiology2010May1538-3687 (Electronic)
0003-9942 (Linking)20457959http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2045795967/5/589 [pii]
10.1001/archneurol.2010.65eng f D Nyholm200515811581158117Nyholm, D.Nilsson Remahl, A. I.Dizdar, N.Constantinescu, R.Holmberg, B.Jansson, R.Aquilonius, S. M.Askmark, H.Department of Neuroscience, Neurology, Uppsala University Hospital, SE-75185 Uppsala, Sweden. dag.nyholm@neurologi.uu.seDuodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.[see comment]NeurologyNeurologyNeurologyN216-236422005Jan 2515668416Nyholm200315861586158617Nyholm, D.Askmark, H.Gomes-Trolin, C.Knutson, T.Lennernas, H.Nystrom, C.Aquilonius, S. M.Department of Neuroscience, Neurology, Uppsala University, Sweden. dag.nyholm@neurologi.uu.seOptimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tabletsClinical NeuropharmacologyClinical NeuropharmacologyClin NeuropharmacolCN156-632632003May-Jun12782919z D Deuschl200615871587158717Deuschl, G.Schade-Brittinger, C.Krack, P.Volkmann, J.Schafer, H.Botzel, K.Daniels, C.Deutschlander, A.Dillmann, U.Eisner, W.Gruber, D.Hamel, W.Herzog, J.Hilker, R.Klebe, S.Kloss, M.Koy, J.Krause, M.Kupsch, A.Lorenz, D.Lorenzl, S.Mehdorn, H. M.Moringlane, J. R.Oertel, W.Pinsker, M. O.Reichmann, H.Reuss, A.Schneider, G. H.Schnitzler, A.Steude, U.Sturm, V.Timmermann, L.Tronnier, V.Trottenberg, T.Wojtecki, L.Wolf, E.Poewe, W.Voges, J.German Parkinson Study Group, Neurostimulation SectionChristian Albrechts University, Kiel, Germany. g.deuschl@neurologie.uni-kiel.deA randomized trial of deep-brain stimulation for Parkinson's disease.[erratum appears in N Engl J Med. 2006 Sep 21;355(12):1289]New England Journal of MedicineNew England Journal of MedicineN Engl J MedNEJM896-90835592006Aug 3116943402Schupbach200727072707270717Schupbach, W. M.Maltete, D.Houeto, J. L.du Montcel, S. T.Mallet, L.Welter, M. L.Gargiulo, M.Behar, C.Bonnet, A. M.Czernecki, V.Pidoux, B.Navarro, S.Dormont, D.Cornu, P.Agid, Y.Centre d'Investigation Clinique, Groupe Hospitalier Pitie-Salpetriere, Paris, France.Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trialNeurologyNeurologyNeurologyN267-716842006/12/08Activities of Daily Living/psychologyAdultAntiparkinson Agents/therapeutic useDeep Brain StimulationFemaleFollow-Up StudiesHumansMaleMiddle AgedNeurosurgical Procedures/*methodsParkinson Disease/epidemiology/psychology/*therapyProspective StudiesQuality of Life/psychologySubthalamic Nucleus/physiologyTime Factors2007Jan 231526-632X (Electronic)17151341http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1715134101.wnl.0000250253.03919.fb [pii]
10.1212/01.wnl.0000250253.03919.fbengWeaver200927042704270417Weaver, F. M.Follett, K.Stern, M.Hur, K.Harris, C.Marks, W. J., Jr.Rothlind, J.Sagher, O.Reda, D.Moy, C. S.Pahwa, R.Burchiel, K.Hogarth, P.Lai, E. C.Duda, J. E.Holloway, K.Samii, A.Horn, S.Bronstein, J.Stoner, G.Heemskerk, J.Huang, G. D.Hines VA Hospital, Center for Management of Complex Chronic Care, Hines, Illinois 60141, USA. Frances.Weaver@va.govBilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trialJAMAJAMAJAMA63-7330112009/01/08AgedCognition*Deep Brain Stimulation/adverse effectsFemaleGlobus PallidusHumansMaleMiddle AgedMotor SkillsParkinson Disease/*therapyQuality of LifeSubthalamic Nucleus2009Jan 71538-3598 (Electronic)19126811http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19126811301/1/63 [pii]
10.1001/jama.2008.929eng $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5 $$If !v h5 5#v #v:V l
t 0 65 5( D Clarke200816821682168217Clarke, C. E.Department of Neurology, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom. c.e.clarke@bham.ac.ukAre delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?Mov DisordMovement DisordersMov DisordMD784-92362008Apr 3018175348Clarke201137803780378017Clarke, C. E.Patel, S.Ives, N.Rick, C.Wheatley, K.Gray, R.Department of Neurology, City Hospital, Sandwell and West Birmingham NHS Trust, Dudley Road, Birmingham, United Kingdom. c.e.clarke@bham.ac.ukShould treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?Movement DisordersMovement DisordersMov DisordMD1187-932672011/04/16Antiparkinson Agents/*therapeutic use*Disability EvaluationEarly DiagnosisHumansParkinson Disease/*diagnosis/*drug therapy/physiopathologyWatchful Waiting/*methods2011Jun1531-8257 (Electronic)
0885-3185 (Linking)21495068http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2149506810.1002/mds.23519engn
D Freed200116011601160117Freed, C. R.Greene, P. E.Breeze, R. E.Tsai, W. Y.DuMouchel, W.Kao, R.Dillon, S.Winfield, H.Culver, S.Trojanowski, J. Q.Eidelberg, D.Fahn, S.Division of Clinical Pharmacology, University of Colorado School of Medicine, Denver 80262, USA.Transplantation of embryonic dopamine neurons for severe Parkinson's disease.[see comment]New England Journal of MedicineNew England Journal of MedicineN Engl J MedNEJM710-9344102001Mar 811236774Olanow200315531553155317Olanow, C. W.Goetz, C. G.Kordower, J. H.Stoessl, A. J.Sossi, V.Brin, M. F.Shannon, K. M.Nauert, G. M.Perl, D. P.Godbold, J.Freeman, T. B.Department of Neurology, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA. warren.olanow@mssm.eduA double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.[see comment]Annals of NeurologyAnnals of NeurologyAnn NeurolAnn403-145432003Sep12953276 ^ 2 0 @ P ` p 2 ( 0 @ P ` p 0 @ P ` p 0 @ P ` p 0 @ P ` p 0 @ P ` p 0 @ P ` p 8 X V ~ _HmH nH sH tH J ` J e\ N o r m a l $x a$ CJ _HaJ mH sH tH R @ R R H e a d i n g 1 $x < @& 5CJ KH \^J aJ P @ P e\ H e a d i n g 2 $x @& 56CJ \]^J aJ D A` D
D e f a u l t P a r a g r a p h F o n t R i@ R 0 T a b l e N o r m a l 4
l 4 a ( k (
0 N o L i s t 4 4 q H e a d e r
9r 4 @ 4 q F o o t e r
9r . ) . q P a g e N u m b e r 6 U !6 R H y p e r l i n k >*B*ph t 3t 1-
T a b l e G r i d 7 :V 0 d a$ H BH U B a l l o o n T e x t CJ OJ QJ ^J aJ \ O Q\ e\ H e a d i n g 2 C h a r ( 56CJ \]^J _HaJ mH sH tH F O bF v
T a b l e T i t l e d a$ CJ aJ J O rJ v T a b l e H e a d e r
x a$ 5CJ aJ PK ! [Content_Types].xmlj0Eжr(Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi} ;~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭? PK ! ֧ 6 _rels/.relsj0 }Q%v/C/} (h"O
= C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_ 6LR7`0̞O,En7Lib/Se е PK ! ky theme/theme/themeManager.xml M
@}w7c(Ebˮ CAǠҟ7՛K
Y,
e.|,H ,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+&
8 PK ! P theme/theme/theme1.xmlYOo6w toc'vuر-Mn iP@I}úama[إ4:l ЯGRX^6؊>$ !)O^rC$y@ /yH*)UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSe bORD۫qu gZo~ٺlAplxpT0+[}`j zA V2Fi@qv֬5\|ʜ̭NleXd sjcs7f
W+Ն7` g ȘJj|h(KD-
dXiJ؇(x$( :;˹! I_TS 1?E ??ZBΪmU/ ?~xY'y5g&/ɋ>GMGeD3Vq%'#q$8K )fw 9:ĵ
x}rxwr:\TZaG*y8IjbRc|XŻǿI
u3KGnD 1NIBs
RuK>V.E L+M2#'fi ~V vl{u8z H
* :( W ☕
~JTe\O*tHGHY }KNP*ݾ˦ TѼ9/#A7qZ $*c?qUnwN%Oi4 =3ڗP
1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g-
eW
)6-rC Sj
id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q% p%m&]caS l=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f
Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ .uχYC6OMf3or$5N HT[XF64T,ќM0E)`#5XY`פ ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R 3U~7+#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vp IYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07% < ҍ PK !
ѐ ' theme/theme/_rels/themeManager.xml.relsM
0wooӺ&݈Э5
6?$Q
,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{ P8g/ ]QAsم(#L[ PK- ! [Content_Types].xmlPK- ! ֧ 6 + _rels/.relsPK- ! ky theme/theme/themeManager.xmlPK- ! P theme/theme/theme1.xmlPK- !
ѐ ' theme/theme/_rels/themeManager.xml.relsPK ]
X
" 4 < QK @O _a o } * ʳ T r t u v : $; (; ~; ; ; < D< k< < < %= L M M N N GN N N O .O N p 0 Ū # _ ) b \ T T s w x y z { | } ~ ^ ` b
$ & m } 7 o$ q$ ) , , . 1 1 4 x8 {8 = @ @ B B 'B (B .B iE JI MI M jQ mQ V 0V FV GV JV W Z Z Z ] ] ` c c ye e e e e f m m 3o 8r ;r #s 3s Is Js Ps u o| q| } = ? A ړ ' ( , C y | + . Q a w x ~ _ · ߸ f i ? R QQQQQ@QQQQ@QQQQQQQ@QQQQ@QQQQQ@QQQQ@QQQQQQQQQQ@QQQQ@QQQ L # A A @ 0 (
B
S ? b ~ b d b b M M 5 5 T T ; ; 9 *urn:schemas-microsoft-com:office:smarttagsplace 8 *urn:schemas-microsoft-com:office:smarttagsCity # - - ; ; D D S S ^ ^ ^ ^ H^ N^ O^ Z^ ' - # % , l m :( A( 9 9 < < W W "s #s ف ކ ? B = L 3 3 3 3 3 3 3 3 3 3 3 3 3 3 } B (B /S 5S 0V GV e e 3s Js ( + , . R x y ~ ` · S } B (B /S 5S 0V GV e e 3s Js ( + R a x ` S :U25= ^` . ^` . pL^p`L . @ ^@ ` . ^` . L^`L . ^` . ^` . PL^P`L . :U 4 %}6_IY -e74 _IY B Z y 3 \ d@ p % a
gt \ EY
R 9 xG Dq ( C b@ ` + @- ^ j _r I~ eD g. 8 [ B ^ W+ Bz /
! /" )m" $ 3L$ H$ c% fp% #a' 0m' ( t2( , , , q, V)- M/ 3 @3 4 '4 w4 #6 77 8 0J9 &; G[; >h; h; ^f< = 5= VdA HC D 7H oJ *qJ p K rP VbQ jR y^S U @U -]U fU YuU :$V 0W 0DW EnX P Z T\ e\ T"] ,H] |] ^^ A` #b h$c be C*e Je pe gg fh ci ,j ^o #p :p r8q =Er Jr \lt ou @ v {v y c} v} ^ D j; } g3 ' T ps F( N q` p m f 0 ~ C~ [S
w u; 6D Q = pa )v # 7m 5t g
l) Z \ ;% 0 dr 2 = Q t ) s@ ] p [ B : sO gA s \S i 5 J% #= zG N @ < v ! q V } %M L FE M% ~ I C V R X G 1- r? a A q9 & K X& ?> , E N . I n s t a n t F o r m a t E N . L a y o u t E N . L i b r a r i e s w < E N I n s t a n t F o r m a t > < E n a b l e d > 1 < / E n a b l e d > < S c a n U n f o r m a t t e d > 1 < / S c a n U n f o r m a t t e d > < S c a n C h a n g e s > 1 < / S c a n C h a n g e s > < / E N I n s t a n t F o r m a t > H< E N L a y o u t > < S t y l e > L a n c e t < / S t y l e > < L e f t D e l i m > { < / L e f t D e l i m > < R i g h t D e l i m > } < / R i g h t D e l i m > < F o n t N a m e > A r i a l < / F o n t N a m e > < F o n t S i z e > 1 2 < / F o n t S i z e > < R e f l i s t T i t l e > < / R e f l i s t T i t l e > < S t a r t i n g R e f n u m > 1 < / S t a r t i n g R e f n u m > < F i r s t L i n e I n d e n t > 0 < / F i r s t L i n e I n d e n t > < H a n g i n g I n d e n t > 7 2 0 < / H a n g i n g I n d e n t > < L i n e S p a c i n g > 0 < / L i n e S p a c i n g > < S p a c e A f t e r > 0 < / S p a c e A f t e r > < / E N L a y o u t > d < E N L i b r a r i e s > < L i b r a r i e s > < i t e m > M o v e m e n t D i s o r d e r s - C o n v e r t e d C o p y . e n l < / i t e m > < / L i b r a r i e s > < / E N L i b r a r i e s > @L 1 2 B C F p @ p : p x @ p L p @ p @ U n k n o w n G * T i m e s N e w R o m a n 5 S y m b o l 3. * A r i a l 5. * a T a h o m a A B C a m b r i a M a t h " 1 h k'sGs n o n o ! 4 2Q HX ? q ! x x 2 T H E D I A G N O S I S A N D T R E A T M E N T O F P A R K I N S O N S D I S E A S E
D r C E C l a r k e P r o f e s s o r C E C l a r k e Oh +'0 , L X
x
4 THE DIAGNOSIS AND TREATMENT OF PARKINSONS DISEASE Dr C E Clarke Normal.dotm Professor C E Clarke 3 Microsoft Office Word @ @ @ d$g@ * n ՜. +,0 h p
SWBH o 3 THE DIAGNOSIS AND TREATMENT OF PARKINSONS DISEASE Title
! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~
R o o t E n t r y F @* D a t a
} 1 T a b l e 1 W o r d D o c u m e n t 8X S u m m a r y I n f o r m a t i o n ( D o c u m e n t S u m m a r y I n f o r m a t i o n 8
C o m p O b j y
F' Microsoft Office Word 97-2003 Document
MSWordDoc Word.Document.8 9q